In the last several years a large number of studies have demonstrated the neurobiological and clinical continuum between depression and Alzheimer’s disease (AD). Depression is a risk factor for the development of AD, and the presence of depressive symptoms significantly increases the conversion of Mild Cognitive Impairment (MCI) into AD.Commonpathophysiological events have been identified in depression and AD, including neuroinflammationwith an aberrant Tumor Necrosis Factor-α(TNF-α)signaling,and an impairment ofBrain-Derived Neurotrophic Factor(BDNF) and Transforming-Growth-Factor-β1 (TGF-β1) signalingTGF-β1is an anti-inflammatory cytokine that exerts neuroprotective effects againstamyloid-β (Aβ)-induced neurodegeneration,andit has a key role in memory formation and synaptic plasticity. TGF-β1 plasmalevels are reduced in major depressed patients (MDD), correlate with depression severity and significantly contribute to treatment resistance in MDD. The deficit of Smad-dependent TGF-β1 signaling is also an early event in AD pathogenesis, whichcontributes to inflammaging and cognitive decline in AD. A long-term treatment with antidepressants such as selective-serotonin-reuptake inhibitors (SSRIs) is known to reduce the risk of AD in patients with depression and, SSRIs, such as fluoxetine, increase the release of TGF-β1 from astrocytes and exert relevant neuroprotective effects in experimental models of AD..

Neurobiological links between depression and AD: the role of TGF-β1 signaling as a new pharmacological target

Caraci F
Primo
Conceptualization
;
Spampinato SF;Caruso G
Writing – Review & Editing
;
Munafò A;Torrisi SA
Writing – Review & Editing
;
Leggio GM
Writing – Review & Editing
;
Drago F;Sortino MA
Conceptualization
;
Copani A
Writing – Original Draft Preparation
2018-01-01

Abstract

In the last several years a large number of studies have demonstrated the neurobiological and clinical continuum between depression and Alzheimer’s disease (AD). Depression is a risk factor for the development of AD, and the presence of depressive symptoms significantly increases the conversion of Mild Cognitive Impairment (MCI) into AD.Commonpathophysiological events have been identified in depression and AD, including neuroinflammationwith an aberrant Tumor Necrosis Factor-α(TNF-α)signaling,and an impairment ofBrain-Derived Neurotrophic Factor(BDNF) and Transforming-Growth-Factor-β1 (TGF-β1) signalingTGF-β1is an anti-inflammatory cytokine that exerts neuroprotective effects againstamyloid-β (Aβ)-induced neurodegeneration,andit has a key role in memory formation and synaptic plasticity. TGF-β1 plasmalevels are reduced in major depressed patients (MDD), correlate with depression severity and significantly contribute to treatment resistance in MDD. The deficit of Smad-dependent TGF-β1 signaling is also an early event in AD pathogenesis, whichcontributes to inflammaging and cognitive decline in AD. A long-term treatment with antidepressants such as selective-serotonin-reuptake inhibitors (SSRIs) is known to reduce the risk of AD in patients with depression and, SSRIs, such as fluoxetine, increase the release of TGF-β1 from astrocytes and exert relevant neuroprotective effects in experimental models of AD..
2018
Alzheimer’s disease, depression, amyloid-β,Transforming-Growth-Factor-β1, antidepressants
File in questo prodotto:
File Dimensione Formato  
Neurobiological links between depression and AD.pdf

solo gestori archivio

Tipologia: Versione Editoriale (PDF)
Dimensione 1.06 MB
Formato Adobe PDF
1.06 MB Adobe PDF   Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11769/316422
Citazioni
  • ???jsp.display-item.citation.pmc??? 76
  • Scopus 124
  • ???jsp.display-item.citation.isi??? 114
social impact